Prime Medicine IPO

Prime Medicine is a biotechnology company focused on developing Prime Editing, a next-generation gene editing technology that can make precise insertions, deletions, and replacements in DNA without requiring double-strand breaks. Founded by pioneering gene editing researchers including David Liu from the Broad Institute, the company aims to address limitations of CRISPR-Cas9 systems by enabling more controlled and versatile genetic modifications with reduced off-target effects.

The company's Prime Editing platform has potential applications across a wide range of genetic diseases, including those caused by small insertions, deletions, and point mutations that account for approximately 89% of known disease-causing genetic variants. Prime Medicine has built a robust pipeline targeting conditions such as chronic granulomatous disease, Wilson disease, and Leber congenital amaurosis 10. The company went public in 2021 and represents one of the most promising next-generation gene editing platforms in clinical development.